

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX CORP.
APOTEX, INC.
Petitioner

v.

ALLERGAN, INC.
Patent Owner

Case IPR: Unassigned
U.S. Patent No. 8,629,111

APOTEX'S EXHIBIT LIST

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Petition for Inter Partes Review of USPN 8,629,111

APOTEX Exhibit #	Description
1001	Acheampong, A., <i>et al.</i> , "Methods of Providing Therapeutic Effects Using Cyclosporin Components," U.S. Patent No. 8,629,111 (filed on August 14, 2013; issued on January 14, 2014)
1002	Ding, S., <i>et al.</i> , "Emulsion Eye Drop For Alleviation of Dry Eye Related Symptoms in Dry Eye Patients and/or Contact Lens Wearers," U.S. Patent No. 5,981,607 (filed on January 20, 1998; issued on November 9, 1999)
1003	Ding, S., <i>et al.</i> "Nonirritating Emulsions For Sensitive Tissue," U.S. Patent No. 5,474,979 (filed on May 17, 1994; issued December 12, 1995)
1004	Sall, K., <i>et al.</i> , "Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Moderate to Severe Dry Eye Disease," <i>Ophthalmology</i> 107: 631-639 (2000)
1005	Declaration of Erning Xia, Ph.D.
1006	<i>Curriculum Vitae</i> of Erning Xia, Ph.D.
1007	Declaration of Christopher N. Ta, Ph.D.
1008	<i>Curriculum Vitae</i> of Christopher N. Ta, Ph.D.
1009	Coles, W.H. and Jaros, P.A., "Dynamics of ocular surface pH," <i>Brit. J. Ophthalmol.</i> 68: 549-552 (1984)
1010	Declaration of Harry C. Boghigian
1011	<i>Curriculum Vitae</i> of Harry C. Boghigian
1012	"Ophthalmic Drug Products for Over-the-Counter Human Use; Final Monograph," <i>Federal Register</i> 53: 7076-93 (1988), available at http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-theCounterOTCDrugs/StatusofOTCRulemakings/ucm071941.htm , (<i>last accessed</i> March 24, 2015)
1013	"CTFA Becomes the Personal Care Products Council," available at http://www.personalcarecouncil.org/ctfa-becomes-personal-care-products-council (<i>last accessed</i> Jan. 29, 2015)
1014	Freeman, J.M., "The Punctum Plug: Evaluation of a New Treatment for the Dry Eye," <i>Transactions American Academy of Ophthalmology and Otolaryngology</i> 79: 874-879 (1975)
1015	Kunert, K., <i>et al.</i> , "Analysis of Topical Cyclosporine Treatment of Patients With Dry Eye Syndrome," <i>Arch Ophthalmol</i> 118: 1489-1496 (2000)

Petition for Inter Partes Review of USPN 8,629,111

APOTEX Exhibit #	Description
1016	Turner, K., <i>et al.</i> , "Interleukin-6 Levels in the Conjunctival Epithelium of Patients with Dry Eye Disease Treated with Cyclosporine Ophthalmic Emulsion," <i>Cornea</i> 19: 492-496 (2000)
1017	Acheampong, A., <i>et al.</i> , "Cyclosporine Distribution Into The Conjunctiva, Cornea, Lacrimal Gland, And Systemic Blood Following Topical Dosing Of Cyclosporine To Rabbit, Dog, And Human Eyes," in <i>Lacrimal Gland, Tear Film, And Dry Eye Syndromes 2 - Basic Science and Clinical Relevance</i> , Plenum Press, New York New York, Chapter 144, pp. 1001-1004 (1998)
1018	Small, D., <i>et al.</i> , "Blood Concentrations of Cyclosporin A During Long-Term Treatment With Cyclosporin A Ophthalmic Emulsions in Patients With Moderate to Severe Dry Eye Disease," <i>Journal of Ocular Pharmacology and Therapeutics</i> 18: 411-418 (2002)
1019	USPN 8,629,111 complete File History
1020	Murphy, R., "The Once and Future Treatment Of Dry Eye," <i>Review of Optometry January 2000 Cover Focus</i> , available at http://legacy.revoptom.com/archive/FEATURES/ro0200f6.htm 6 (last accessed October 21, 2014)
1021	Inatomi, T., <i>et al.</i> , "Expression of Secretory Mucin Genes by Human Conjunctival Epithelia," <i>Invest Ophthalmol</i> 37: 1684-1692 (1996)
1022	Solomon, A., <i>et al.</i> , "Doxycycline Inhibition of Interleukin-1 in the Corneal Epithelium," <i>Invest Ophthalmol Vis Sci</i> 41: 2544-2557 (2000)
1023	Stevenson, D., <i>et al.</i> , "Efficacy and Safety of Cyclosporin A Ophthalmic Emulsion in the Treatment of Moderate-to-Severe Dry Eye Disease," <i>Ophthalmology</i> 107: 967-974 (2000)
1024	"Personal Care Production Council," available at http://www.personalcarecouncil.org/ (last accessed Jan. 29, 2015)
1025	Allergan Dry Eye Product Portfolio Fact Sheet, downloaded from http://www.allergan.com/assets/pdf/dry_eye_product_portfolio_fact_sheet.pdf , last accessed January 26, 2015
1026	"Certain Steroid Preparations for Ophthalmic and/or Otic Use," in <i>Federal Register</i> 41: 34340-34342 (1976)
1027	<i>Intentionally Left Blank</i>
1028	Pflugfelder, S.C., <i>et al.</i> , "The Diagnosis and Management of Dry Eye-A Twenty-five-Year Review," <i>Cornea</i> 19: 644-649 (2000)
1029	Albietz, J.M., "Dry eye: An Update On Clinical Diagnosis, Management and Promising New Treatments," <i>Clin & Exp. Optometry</i> 84: 4-18 (2001)

Petition for Inter Partes Review of USPN 8,629,111

APOTEX Exhibit #	Description
1030	Liu, K. <i>et al.</i> , "Synthetic Approaches to the 2010 New Drugs," <i>Bioorganic & Medicinal Chemistry</i> 20: 1155-1174 (2012)
1031	<i>Intentionally Left Blank</i>
1032	<i>Intentionally Left Blank</i>
1033	Goto, E. <i>et al.</i> , "Low-concentration Homogenized Castor Oil Eye Drops for Noninflamed Obstructive Meibomian Gland Dysfunction," <i>Ophthalmology</i> 109: 2030-2035 (2002)
1034	Certain Ophthalmic Combination Drugs Containing a Steroid and Anti-Infective(s) for Human Use; Drug Efficacy Study Implementation; Amendment," <i>Federal Register</i> 47: 21296-21301 (1982)
1035	Yeh, S. <i>et al.</i> , "Apoptosis of Ocular Surface Cells in Experimentally Induced Dry Eye," <i>Invest. Ophthalmology & Visual Sci.</i> 44:124-129 (2003)
1036	Lemp, M.A., "Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes," <i>CLAO</i> 21: 221-232 (1995)
1037	Gilbard, J.P., "Dry Eye, Blepharitis, and Chronic Eye Irritation: Divide and Conquer," <i>J. Ophthalmic Nurs. Technol.</i> 18: 109-115 (1999)
1038	Napper, G. <i>et al.</i> , "Ocular therapeutics," <i>Clin. & Exp. Optometry</i> 86: 414-415 (2003)
1039	Allergan, Inc. 2002 Annual Report, downloaded from http://agn.client.shareholder.com/financials.cfm , (last accessed Jan. 16, 2015)
1040	Taban, M. <i>et al.</i> , "Update on Punctal Plugs," <i>Comp. Ophthalmology Update</i> 7: 205-212 (2006)
1041	Chanana, G., and Sheth, B., "Particle Size Reduction of Emulsions by Formulation Design-II: Effect of Oil and Surfactant Concentration," <i>PDA J. Pharm. Sci. & Tech.</i> , 49: 71-76 (1995)
1042	Chung, H. <i>et al.</i> , "Oil components modulate physical characteristics and function of the natural oil emulsions as drug or gene delivery system," <i>J. Controlled Release</i> 71:339- 350 (2001)
1043	RESTASIS® Approved Label, downloaded from the Allergan website https://www.restasisprofessional.com/RestasisProfessional/FullPrescribingInformation , last accessed January 28, 2015

Petition for Inter Partes Review of USPN 8,629,111

<i>APOTEX Exhibit #</i>	<i>Description</i>
1044	American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern [®] Guidelines. Dry Eye Syndrome. San Francisco, CA: American Academy of Ophthalmology (2013), available at: www.aao.org/ppp (last accessed December 31, 2014)
1045	De Paiva, C.S., and Pflugfelder, S.C., "Rationale for Anti-Inflammatory Therapy in Dry Eye Syndrome," <i>Arq. Bras. Oftalmol.</i> 71: 89-95 (2008)
1046	Autry, J.C., "Mix It Up: When to Call a Compounding Pharmacist," <i>Review of Optometry</i> 149: 30-37 (July 15, 2012)
1047	Mann, E., "Drugs used in the treatment of dry eye syndrome, anti-inflammatory drugs and topical anti-allergy drugs," <i>Continuing Education & Training</i> pp. 30-40 (2007)
1048	Allergan, Inc. 2001 Annual Report, downloaded from http://agn.client.shareholder.com/financials.cfm , last accessed January 1, 2015
1049	Allergan, Inc. 2003 Annual Report, downloaded from http://agn.client.shareholder.com/financials.cfm , last accessed January 1, 2015
1050	Allergan, Inc. 2004 Annual Report, downloaded from http://agn.client.shareholder.com/financials.cfm , last accessed January 1, 2015
1051	Allergan, Inc. 2005 Annual Report, downloaded from http://agn.client.shareholder.com/financials.cfm , last accessed January 1, 2015
1052	Allergan, Inc. 2006 Annual Report, downloaded from http://agn.client.shareholder.com/financials.cfm , last accessed January 1, 2015
1053	Allergan, Inc. 2009 Annual Report, downloaded from http://agn.client.shareholder.com/financials.cfm , last accessed January 1, 2015
1054	Allergan, Inc. 2010 Annual Report, downloaded from http://agn.client.shareholder.com/financials.cfm , last accessed January 1, 2015

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.